BCR and lymphoma: While transcriptomics have disclosed oncogenic driver mutations, altered gene expression patterns, differential signatures of lymphoma and leukemia subtypes, as well as potential cells of origin, the clinical use of tyrosine kinase inhibitors (TKI) in patients has underscored the complex and pathologic signaling roles orchestrated by the BCR (52–56).